← Browse by Condition
Medical Condition

brca2 mutation

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1, Phase 2
NCT06395519 Phase 1, Phase 2
Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Enrollment
120 pts
Location
United States
Sponsor
858 Therapeutics, Inc.
View Trial →